c-myc-PT3EF1a Citations (15)
Originally described in: A functional mTORC1 signaling is indispensable for c-Myc driven hepatocarcinogenesis.Liu P, Ge M, Hu J, Li X, Che L, Sun K, Cheng L, Huang Y, Pilo MG, Cigliano A, Pes GM, Pascale RM, Brozzetti S, Vidili G, Porcu A, Cossu A, Palmieri G, Sini MC, Ribback S, Dombrowski F, Tao J, Calvisi DF, Chen L, Chen X Hepatology. 2017 Mar 30. doi: 10.1002/hep.29183. PubMed Journal
Articles Citing c-myc-PT3EF1a
| Articles |
|---|
| Focal adhesion kinase activation limits efficacy of Dasatinib in c-Myc driven hepatocellular carcinoma. Liu X, Song X, Zhang J, Xu Z, Che L, Qiao Y, Ortiz Pedraza Y, Cigliano A, Pascale RM, Calvisi DF, Liu Y, Chen X. Cancer Med. 2018 Dec;7(12):6170-6181. doi: 10.1002/cam4.1777. Epub 2018 Oct 28. PubMed |
| Inducing and exploiting vulnerabilities for the treatment of liver cancer. Wang C, Vegna S, Jin H, Benedict B, Lieftink C, Ramirez C, de Oliveira RL, Morris B, Gadiot J, Wang W, du Chatinier A, Wang L, Gao D, Evers B, Jin G, Xue Z, Schepers A, Jochems F, Sanchez AM, Mainardi S, Te Riele H, Beijersbergen RL, Qin W, Akkari L, Bernards R. Nature. 2019 Oct;574(7777):268-272. doi: 10.1038/s41586-019-1607-3. Epub 2019 Oct 2. PubMed |
| Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer Metastasis. Leibold J, Ruscetti M, Cao Z, Ho YJ, Baslan T, Zou M, Abida W, Feucht J, Han T, Barriga FM, Tsanov KM, Zamechek L, Kulick A, Amor C, Tian S, Rybczyk K, Salgado NR, Sanchez-Rivera FJ, Watson PA, de Stanchina E, Wilkinson JE, Dow LE, Abate-Shen C, Sawyers CL, Lowe SW. Cancer Discov. 2020 Jul;10(7):1038-1057. doi: 10.1158/2159-8290.CD-19-1242. Epub 2020 May 6. PubMed |
| FBXL6 governs c-MYC to promote hepatocellular carcinoma through ubiquitination and stabilization of HSP90AA1. Shi W, Feng L, Dong S, Ning Z, Hua Y, Liu L, Chen Z, Meng Z. Cell Commun Signal. 2020 Jun 23;18(1):100. doi: 10.1186/s12964-020-00604-y. PubMed |
| Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function. Jiang T, Sanchez-Rivera FJ, Soto-Feliciano YM, Yang Q, Song CQ, Bhuatkar A, Haynes CM, Hemann MT, Xue W. Hepatology. 2021 Jul;74(1):233-247. doi: 10.1002/hep.31685. Epub 2021 Jul 12. PubMed |
| EGFR activation limits the response of liver cancer to lenvatinib. Jin H, Shi Y, Lv Y, Yuan S, Ramirez CFA, Lieftink C, Wang L, Wang S, Wang C, Dias MH, Jochems F, Yang Y, Bosma A, Hijmans EM, de Groot MHP, Vegna S, Cui D, Zhou Y, Ling J, Wang H, Guo Y, Zheng X, Isima N, Wu H, Sun C, Beijersbergen RL, Akkari L, Zhou W, Zhai B, Qin W, Bernards R. Nature. 2021 Jul;595(7869):730-734. doi: 10.1038/s41586-021-03741-7. Epub 2021 Jul 21. PubMed |
| SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma. Du L, Liu W, Aldana-Masangkay G, Pozhitkov A, Pichiorri F, Chen Y, Rosen ST. J Exp Clin Cancer Res. 2022 Jan 4;41(1):8. doi: 10.1186/s13046-021-02226-9. PubMed |
A flexible split prime editor using truncated reverse transcriptase improves dual-AAV delivery in mouse liver.
Zheng C, Liang SQ, Liu B, Liu P, Kwan SY, Wolfe SA, Xue W.
Mol Ther. 2022 Mar 2;30(3):1343-1351. doi: 10.1016/j.ymthe.2022.01.005. Epub 2022 Jan 5.
PubMed
Associated Plasmids |
| FBXL6 is dysregulated in keloids and promotes keloid fibroblast growth by inducing c-Myc expression. Feng G, Sun H, Piao M. Int Wound J. 2022 May 23. doi: 10.1111/iwj.13847. PubMed |
| Intravital electrochemical nanosensor as a tool for the measurement of reactive oxygen/nitrogen species in liver diseases. Abakumova T, Vaneev A, Naumenko V, Shokhina A, Belousov V, Mikaelyan A, Balysheva K, Gorelkin P, Erofeev A, Zatsepin T. J Nanobiotechnology. 2022 Nov 24;20(1):497. doi: 10.1186/s12951-022-01688-z. PubMed |
| Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma. Mulero-Sanchez A, Ramirez CFA, du Chatinier A, Wang H, Koomen SJI, Song JY, de Groot MHP, Lieftink C, Bosma A, Burylo A, van Tellingen O, Beijersbergen RL, Wang C, Akkari L, Bernards R, Mainardi S. Mol Oncol. 2023 Jun;17(6):964-980. doi: 10.1002/1878-0261.13377. Epub 2023 Feb 9. PubMed |
| Androgen receptor variant 7 exacerbates hepatocarcinogenesis in a c-MYC-driven mouse HCC model. Kido T, Lau YC. Oncogenesis. 2023 Feb 6;12(1):4. doi: 10.1038/s41389-023-00449-3. PubMed |
| MLL3 regulates the CDKN2A tumor suppressor locus in liver cancer. Zhu C, Soto-Feliciano YM, Morris JP, Huang CH, Koche RP, Ho YJ, Banito A, Chen CW, Shroff A, Tian S, Livshits G, Chen CC, Fennell M, Armstrong SA, Allis CD, Tschaharganeh DF, Lowe SW. Elife. 2023 Jun 1;12:e80854. doi: 10.7554/eLife.80854. PubMed |
| Multimodal label-free imaging of murine hepatocellular carcinoma with a subcellular resolution. Chebotarev AS, Ledyaeva VS, Patsap OI, Ivanov AA, Fedotov AB, Belousov VV, Shokhina AG, Lanin AA. J Biophotonics. 2023 Dec;16(12):e202300228. doi: 10.1002/jbio.202300228. Epub 2023 Sep 13. PubMed |
Low glucose metabolite 3-phosphoglycerate switches PHGDH from serine synthesis to p53 activation to control cell fate.
Wu YQ, Zhang CS, Xiong J, Cai DQ, Wang CZ, Wang Y, Liu YH, Wang Y, Li Y, Wu J, Wu J, Lan B, Wang X, Chen S, Cao X, Wei X, Hu HH, Guo H, Yu Y, Ghafoor A, Xie C, Wu Y, Xu Z, Zhang C, Zhu M, Huang X, Sun X, Lin SY, Piao HL, Zhou J, Lin SC.
Cell Res. 2023 Nov;33(11):835-850. doi: 10.1038/s41422-023-00874-4. Epub 2023 Sep 19.
PubMed
Associated Plasmids |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.